Thursday, April 7th, 2016 - RnR Market Research adds Attention Deficit Hyperactivity Disorder (ADHD) Market Research 2016 to its database, providing in-depth, high quality, transparent and market-driven, expert’s analysis.

Companies Profile discussed in this research:  Alcobra Ltd, Amarantus Bioscience Holdings, Inc., APeT Holding BV, Arbor Pharmaceuticals, LLC., BCWorld Pharm Co. Ltd., Collegium Pharmaceutical, Inc., Curemark, LLC, Domain Therapeutics SA, DURECT Corporation, Ensysce Biosciences Inc., H. Lundbeck A/S, Heptares Therapeutics Limited, Highland Therapeutics, Inc. ,Hisamitsu Pharmaceutical Co., Inc., Integrative Research Laboratories Sweden AB, Intra-Cellular Therapies, Inc., INVENT Pharmaceuticals, Inc., KemPharm, Inc., Luc Therapeutics, Inc., Medgenics Inc., Merck & Co., Inc., Neos Therapeutics, Inc., NeuroDerm Ltd., Neurovance, Inc., NLS Pharma Group, P2D Bioscience, Polleo Pharma Limited, Reviva Pharmaceuticals Inc., Shire Plc, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., Taisho Pharmaceutical Holdings Co., Ltd., TRImaran Pharma, Inc. and Vernalis Plc.

Inquire more about this research

The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete research across 196 pages



  • The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD)
  • The report reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Attention Deficit Hyperactivity Disorder (ADHD) therapeutics and enlists all their major and minor projects
  • The report assesses Attention Deficit Hyperactivity Disorder (ADHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

File Library

Contact Profile

RnR Market Research

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us: 

G+ / Google Plus:



RSS / Feeds:

Ritesh Tiwari
P: + 1 888 391 5441


Crohn’s Disease (Regional Enteritis) Therapeutic Products under Development, Key Players in Crohn’s Disease (Regional Enteritis) Therapeutics, Crohn’s Disease (Regional Enteritis) Pipeline Overview, Crohn’s Disease (Regional Enteritis) Pipeline, Crohn’s D




More Formats